Results 131 to 140 of about 15,193 (187)

State‐of‐the‐Art Strategies for Circular RNA in Cancers: Opportunity and Challenge

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Overview of circular RNA in tumors. ABSTRACT Circular RNAs (circRNAs) are characterized by their covalently closed structure, remarkable stability, and precise spatiotemporal regulation, evolving from once‐overlooked transcriptional byproducts to pivotal molecular regulators.
Zehao Ding   +6 more
wiley   +1 more source

Stem Cell Therapy for Inflammatory Diseases: Progress, Challenges, and Future Directions

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Stem cells offer multifaceted therapeutic approaches for inflammatory diseases, each exhibiting distinct therapeutic properties. Hematopoietic stem cells, primarily through hematopoietic stem cell transplantation (HSCT), can effectively remodel the immune environment, showing particular promise in treating genetically linked cases.
Chen Wu   +4 more
wiley   +1 more source

Bearing Capacity of Tension Steel Piles in Thinly Inter‐Layered Soils: Numerical Class‐A Prediction vs. Field Measurements

open access: yesInternational Journal for Numerical and Analytical Methods in Geomechanics, Volume 50, Issue 3, Page 1430-1450, 25 February 2026.
ABSTRACT This study investigates the bearing capacity of tension piles and pile‐soil interaction during loading. Discrepancies between predicted and measured bearing capacities in previous tests motivated the study, where analytical methods showed considerable scatter and uncertainties in design.
Diaa Alkateeb, Jürgen Grabe
wiley   +1 more source

Non‐Coding RNAs in Breast Cancer Radioresistance: Mechanisms, Functional Roles and Translational Potentials

open access: yesCell Proliferation, Volume 59, Issue 2, February 2026.
Non‐coding RNAs (ncRNAs) regulate breast cancer radioresistance via cell cycle, DNA repair and tumour microenvironment pathways. Targeting ncRNAs (e.g., HOTAIR and miR‐155) with RNA‐based therapies (ASOs and CRISPR) shows promise but faces delivery challenges.
Xiaohui Zhao   +8 more
wiley   +1 more source

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

open access: yesCell Proliferation, Volume 59, Issue 2, February 2026.
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu   +5 more
wiley   +1 more source

Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma. [PDF]

open access: yesCancers (Basel), 2021
Boukrout N   +9 more
europepmc   +1 more source

MSC‐Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges—A Narrative Review

open access: yesInternational Journal of Dermatology, Volume 65, Issue 2, Page 257-272, February 2026.
ABSTRACT Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell‐based therapies.
Marcela da Costa Pereira Cestari   +2 more
wiley   +1 more source

Mining Potential Therapeutic Targets for T Cell Exhaustion in Osteoarthritis by Integrating Mendelian Randomization and Single‐Cell Sequencing

open access: yesThe FASEB Journal, Volume 40, Issue 2, 31 January 2026.
This study conducted an integrated analysis using multi‐source data, with specific data sources including the GEO database (encompassing datasets GSE55235, GSE55457, and GSE152805), literature‐mined gene sets, and the IEU OpenGWAS database (dataset ebi‐a‐GCST005814).
Jiahong Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy